This study is framed to evaluate the effect of medicated enema (Rasnadi Basti) in the patients of multiple joints pain disease Vatarakta (Gouty Arthritis)

Evaluation Of Rasnadi Basti In The Management Of Vatarakta (Gouty Arthritis) - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/07/043915

Enrollment

Registered

2022-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified Health Condition 2: M958- Other specified acquired deformities of musculoskeletal system

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Sujects with clinical features of Vatarakta. 2.Subjects with chronicity of disease more than 6 months and less than 2 years. 3.Subjects of either sex between age group of 30-60 years. The paitents fit for Basti karma. 5.Subject with uric acid level above 6mg/dl for females and 7mg/dl for males.

Exclusion criteria

Exclusion criteria: 1.Subject with clinical features other than Vatarakta. 2.Subjects with chronicity of disease less than 6 months and above 2 years. 3.Subjects of either sex below 30 years and above 2 years. 4.The paitents unfit for Basti karma. 5.Subjects with uric acid above 9mg/dl. 6.All connective tissue disorders other than Gouty Arthritis. 7.Systemic Lupus Erythematous and other auto immune disorders. 8.Paitents having systemic pathologies like cardiac disease, renal disease and hypertension. 9.Subjects with uncontrolled diabetes, systemic disorders and endocrine disorders. 10.Paitents having tuberculosis of spine,spinal tumors, vertebral fractures, surgical conditions and pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
The outcome will be assessed on the basis of objective parameters like Sandhi Shoola (Joint pain), Sandhi Shotha (Joint swelling), Sparsh Asahatvam (Tenderness), Daha (Burning sensation), Raaga (Erythema), Twak Vaivarnya (Discoloration), Stabdhata (Stiffness), Toda (Piercing sensation.Timepoint: At baseline, 11th day, 30th day and 60th day	—

Secondary

Measure	Time frame
The outcome will be assessed on the basis of objective parameters like Range of movement, VAS scale- for pain assessment, CBC, ESR, CRP, Serum uric acid, Urine Examination at an interval of 11th, 30th, 60th days. Timepoint: At baseline, 11th day, 30th day and 60th day	—

Countries

India

Contacts

Public ContactDr Jaibir Singh

Shri Krishna Ayush university kurukshetra

drashishhmehta@gmail.com9468319930

Outcome results